Regen Biopharma Inc (RGBP) 0.1499 $RGBP
Regen BioPharma, Inc. Cancer Stem Cell Gene Target Shown to be a Key Mediator of Cancer Immune Surveillance by Independent Researchers
PR Newswire - Tue Sep 29, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) reported today that an independent research laboratory has published that the cancer stem cell target gene NR2F6 is a key gene that controls anti-tumor immune surveillance. Regen BioPharma has several pieces of intellectual property related to NR2F6 including issued United States patent # 9,091,696, Modulation of NR2F6 and methods and uses thereof, that covers methods for identifying compounds that can modulate the function of NR2F6 in mammalian cells and several other applications with priority dates of 2008 including patent application # 14571262 that covers use of gene silenicing with short interfering nucleic acid (siNA) antisense, short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) for treatment for cancer.
Regen BioPharma, Inc. Director of Molecular Therapeutics to Speak at Stem Cell Conference Regarding Leukemia Research Being Conducted by the Company
PR Newswire - Mon Sep 28, 7:30AM CDT
Dr. Christine Ichim will present at Stem Cell Meeting on the Mesa
Regen BioPharma, Inc. Announces Positive Results from GLP Safety Study for HemaXellerate
PR Newswire - Fri Sep 25, 7:30AM CDT
Final Experiments Requested by FDA Completed
Entest BioMedical Updates Company Status and Future Plans
PR Newswire - Thu Sep 24, 9:30AM CDT
Entest BioMedical Inc. (PINK: ENTB) discussed the Company's current status and future plans.
Regen Biopharma Inc. Initiates Small Molecule Hit Validation Study on Cancer Stem Cell Target Gene
PR Newswire - Wed Sep 23, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today that it has initiated studies for its small molecule drug discovery platform on its cancer stem cell target gene. These studies are expected to be completed within the next two months.
Regen BioPharma, Inc. Files Utility Patent Application on Immune Based Therapy for Cancer
PR Newswire - Wed Sep 16, 7:30AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) and (PINK: RGBP) announced today the filing of a utility patent application with the United States Patent and Trademark Office covering a novel cancer immunotherapy which induces activation of dendritic cells inside the body in order to stimulate immune-based rejection of cancer. The application builds on Regen's existing expertise in the area of dendritic cells including publications together with scientific advisory board member Dr. Wei-Ping Min (1-3), Professor at the University of Western Ontario, as well as purchase of issued patent # 8,389,708.
Regen BioPharma, Inc. BORIS Gene Silencing Technology Successfully Utilized by Independent Researchers to Kill Breast Cancer and Colon Cancer Stem Cells
PR Newswire - Mon Aug 24, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) reported today the successful implementation of its gene silencing technology, covered by patent # 8,263,571, in killing cancer stem cells. The technology involves using RNA interference to block expression of the cancer-sustaining gene Brother of the Regulator of Imprinted Sites (BORIS) by a process termed "gene silencing".
Regen BioPharma Inc. Progresses in FDA Responses to dCellVax Clinical Trial Questions
PR Newswire - Mon Aug 10, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) updated shareholders regarding progress achieved in its ongoing experiments performed to address FDA questions on its Investigational New Drug Application (IND) #16200 for dCellVax. IND #16200 is an application to conduct a Phase I clinical trial of the Company's dCellVax immunotherapeutic product as a treatment for advanced breast cancer patients.
Regen BioPharma, Inc. Successfully Completes in Life Portion of Experiments Requested by FDA for HemaXellerate Pre-Clinical Study
PR Newswire - Tue Jul 21, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) announced today positive preliminary safety results from the in life portion of an experimental study requested by the US Food and Drug Administration (FDA) assessing toxicity in mice treated with high doses of HemaXellerate, a proprietary therapy under development by Regen Biopharma, Inc. After a 14 day observation period, male and female mice administered with higher than 10-fold the proposed human dose on a per kilogram basis exhibited no adverse effects. Regen expects to receive an audited report on full completion of the experiments in mid-September.
Regen BioPharma, Inc. Presents Preclinical Proof-of-Concept of DiffronC Effectiveness at the International Society for Stem Cell Research (ISSCR) Annual Meeting
PR Newswire - Tue Jul 14, 7:30AM CDT
Regen BioPharma Inc (OTCBB: RGBP) (OTC PINK: RGBP) announced today that Dr. Christine Ichim, the Company's Director of Molecular Therapeutics presented preclinical data regarding its DiffronC technology( a constituent of its Differentiation Therapy Platform) at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden on June 24th, 2015.
Regen BioPharma doses mice under its safety and tolerability study of HemaXellerate for aplastic anemia
M2 - Fri Jul 10, 3:36AM CDT
Biotechnology company Regen BioPharma (OTCBB:RGBP) (OTC PINK:RGBP) announced on Thursday the successful dosing of mice lacking an immune system under its safety and tolerability study with its proprietary aplastic anemia cell therapy drug candidate, HemaXellerate.
New Studies & Research Evaluating Stem Cell Therapy Treatments for Bone Marrow Diseases & Conditions Look to Identify Next-Generation Therapies For New Pre-Clinical and Phase I/II Clinical Trials
PR Newswire - Thu Jul 09, 7:30AM CDT
Researchers & Biotech companies are constantly searching for tailor-made treatment plans for bone marrow conditions such as aplastic anemia as part of an emerging precision medicine movement which likely will help doctors optimize treatment for this rare and deadly blood condition. Even with the Biotechnology struggling a bit this week in markets, companies in focus today with news and current developments are Regen BioPharma, Inc. (OTCBB: RGBP), Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), Horizon Pharma plc (NASDAQ: HZNP), AstraZeneca Pharmaceuticals Co. (NYSE: AZN) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
RPTP: 5.99 (+0.10), IRWD: 11.36 (+0.24), AZN: 32.23 (-0.16), HZNP: 19.51 (+1.19), OCLS: 1.22 (+0.03)
Regen BioPharma, Inc. Reports Successful Dosing of HemaXellerate in FDA-Requested GLP Animal Study
PR Newswire - Thu Jul 09, 6:45AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) (OTC: RGBP) reported today the successful dosing of mice lacking an immune system in a safety and tolerability study with HemaXellerate, the Company's proprietary aplastic anemia cell therapy drug candidate. The experiment is being conducted under Good Laboratory Practices (cGLP) by Charles River Laboratories. Charles River Laboratories, established in 1947, is a well respected NYSE-traded contract research organization with 8,500 employees specializing in a variety of pre-clinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries.
Regen BioPharma, Inc. Announces Presentation at the International Society for Stem Cell Research 13th Annual Meeting in Stockholm, Sweden
PR Newswire - Tue Jun 16, 7:30AM CDT
Regen BioPharma Inc (OTCBB: RGBP) (OTC PINK: RGBP) announced today that its abstract was accepted for presentation at the International Society for Stem Cell Research Annual Meeting, June 24-27, in Stockholm, Sweden. Dr. Christine Ichim, the Company's Director of Molecular Therapeutics, will be presenting preclinical data delineating the effects of the Company's gene silencing drugs on stem cells.
Regen BioPharma, Inc. Receives Notice of Allowance for U.S. Patent for Screening of Small Molecules Against Its Nuclear Receptor Target
Marketwired - Fri Jun 12, 9:16AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that it received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application # 13/652,395. This patent, with a priority date of 2008, covers screening mechanisms for identification of small molecules that can modulate the function of a nuclear receptor target that was shown by Dr. Christine Ichim, Regen's Director of Molecular Therapeutics and University of Toronto Hematologist Dr. Richard Wells to be involved in maintenance of the cancer stem cells.
Advanced Immunotherapy Clinical Trials for Cancer Therapies & Breast Cancer Treatments Focus on Developing Innovative Therapeutics & Gene-Silencing Cell Studies
PR Newswire - Wed Jun 10, 7:35AM CDT
Clinical Trials and Innovation Therapies continue to have the potential to drive the pharma and biotech sectors for the final six months of 2015 as forecasts point to the potential for another prosperous year. Cancer new treatments show promise of immuno-oncology therapies as further studies & trials continue to progress. Biotech Companies in focus today are Regen BioPharma, Inc. (OTC: RGBP), Sanofi SA (NYSE: SNY), Vical Incorporated (NASDAQ: VICL), RXi Pharmaceuticals Corporation (NASDAQ: RXII), Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI) & Neuralstem, Inc. (NYSE: CUR)
VICL: 0.43 (unch), RXII: 0.50 (+0.02), RCPI: 0.88 (unch), SNY: 48.75 (+0.03), CUR: 1.33 (+0.03)
Cancer Clinical Trials Expert Dr. Santosh Kesari to Assist Regen BioPharma, Inc. in Addressing FDA Questions Regarding Planned dCellVax Immunotherapy Clinical Trial for Breast Cancer
PR Newswire - Wed Jun 10, 6:55AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) (OTC: RGBP) announced today the initiation of a collaboration with Dr. Santosh Kesari , Professor and Director of Neuro-oncology at University of California San Diego . The goals of the collaboration is to address questions posed by the FDA regarding Regn BioPharma, Inc.'s planned Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer and to modify the existing Investigational New Drug application in order to maximize the probability of clinical trial success . The proposed trial will recruit 10 patients with metastatic breast cancer and will involve 4 monthly injections of the dCellVax gene-silenced dendritic cell therapy. The trial will last one year, with tumor assessment before therapy and at 6 and 12 months.
Regen BioPharma, Inc. Recruits Retinoid Experts Dr. Hinrich Gronemeyer, Dr. William S. Blaner, and Dr. Louise Purton to Serve on Scientific Advisory Board
Marketwired - Thu Jun 04, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the appointment of Dr. Hinrich Gronemeyer, Dr. William S. Blaner, and Dr. Louise Purton to its Scientific Advisory Board. These three experts in the field of retinoid biology have been recruited by Regen BioPharma, Inc. in order to provide the Company with the expertise necessary to accelerate Regen's differentiation therapy small molecule drug discovery platform. This platform aims to design small molecules that can induce differentiation of cancer stem cells by designing ligands to nuclear receptors involved in maintaining stem cell properties of cancer stem cells.
Regen BioPharma Files Patent Application on mRNA Dendritic Cell Cancer Immunotherapeutic
Marketwired - Wed May 27, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the filing of a United States patent application covering mRNA delivered tumor antigens to dendritic cells as a means of inducing tumor immunity. The current work builds upon the Company's Cancer Immunotherapy Platform. This patent application covers intellectual property that provides a means of specifically inducing dendritic cells to internally generate tumor antigens, a process which is believed to be more effective then exogenously administering antigens to dendritic cells. The majority of dendritic cell therapeutics involve "feeding" dendritic cells antigens, this leads to a different type of immune response than if the antigens are generated inside of the dendritic cell.
Regen BioPharma, Inc. Makes Three Presentations at the 13th International Symposium on Myelodysplastic Syndromes Held April 29 to May 2, 2015 in Washington, DC
Marketwired - Tue May 05, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that the Company has made presentations at 13th International Symposium on Myelodysplastic Syndromes held April 29 to May 2, 2015 in Washington, D.C.
Regen BioPharma, Inc. Cancer Stem Cell Gene Target Shown to be a Key Mediator of Cancer Immune Surveillance by Independent Researchers
PR Newswire - Tue Sep 29, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) reported today that an independent research laboratory has published that the cancer stem cell target gene NR2F6 is a key gene that controls anti-tumor immune surveillance. Regen BioPharma has several pieces of intellectual property related to NR2F6 including issued United States patent # 9,091,696, Modulation of NR2F6 and methods and uses thereof, that covers methods for identifying compounds that can modulate the function of NR2F6 in mammalian cells and several other applications with priority dates of 2008 including patent application # 14571262 that covers use of gene silenicing with short interfering nucleic acid (siNA) antisense, short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) for treatment for cancer.
Regen BioPharma, Inc. Director of Molecular Therapeutics to Speak at Stem Cell Conference Regarding Leukemia Research Being Conducted by the Company
PR Newswire - Mon Sep 28, 7:30AM CDT
Dr. Christine Ichim will present at Stem Cell Meeting on the Mesa
Regen BioPharma, Inc. Announces Positive Results from GLP Safety Study for HemaXellerate
PR Newswire - Fri Sep 25, 7:30AM CDT
Final Experiments Requested by FDA Completed
Entest BioMedical Updates Company Status and Future Plans
PR Newswire - Thu Sep 24, 9:30AM CDT
Entest BioMedical Inc. (PINK: ENTB) discussed the Company's current status and future plans.
Regen Biopharma Inc. Initiates Small Molecule Hit Validation Study on Cancer Stem Cell Target Gene
PR Newswire - Wed Sep 23, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today that it has initiated studies for its small molecule drug discovery platform on its cancer stem cell target gene. These studies are expected to be completed within the next two months.
Regen BioPharma, Inc. Files Utility Patent Application on Immune Based Therapy for Cancer
PR Newswire - Wed Sep 16, 7:30AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) and (PINK: RGBP) announced today the filing of a utility patent application with the United States Patent and Trademark Office covering a novel cancer immunotherapy which induces activation of dendritic cells inside the body in order to stimulate immune-based rejection of cancer. The application builds on Regen's existing expertise in the area of dendritic cells including publications together with scientific advisory board member Dr. Wei-Ping Min (1-3), Professor at the University of Western Ontario, as well as purchase of issued patent # 8,389,708.
Regen BioPharma, Inc. BORIS Gene Silencing Technology Successfully Utilized by Independent Researchers to Kill Breast Cancer and Colon Cancer Stem Cells
PR Newswire - Mon Aug 24, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) reported today the successful implementation of its gene silencing technology, covered by patent # 8,263,571, in killing cancer stem cells. The technology involves using RNA interference to block expression of the cancer-sustaining gene Brother of the Regulator of Imprinted Sites (BORIS) by a process termed "gene silencing".
Regen BioPharma Inc. Progresses in FDA Responses to dCellVax Clinical Trial Questions
PR Newswire - Mon Aug 10, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) updated shareholders regarding progress achieved in its ongoing experiments performed to address FDA questions on its Investigational New Drug Application (IND) #16200 for dCellVax. IND #16200 is an application to conduct a Phase I clinical trial of the Company's dCellVax immunotherapeutic product as a treatment for advanced breast cancer patients.
Regen BioPharma, Inc. Successfully Completes in Life Portion of Experiments Requested by FDA for HemaXellerate Pre-Clinical Study
PR Newswire - Tue Jul 21, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) announced today positive preliminary safety results from the in life portion of an experimental study requested by the US Food and Drug Administration (FDA) assessing toxicity in mice treated with high doses of HemaXellerate, a proprietary therapy under development by Regen Biopharma, Inc. After a 14 day observation period, male and female mice administered with higher than 10-fold the proposed human dose on a per kilogram basis exhibited no adverse effects. Regen expects to receive an audited report on full completion of the experiments in mid-September.
Regen BioPharma, Inc. Presents Preclinical Proof-of-Concept of DiffronC Effectiveness at the International Society for Stem Cell Research (ISSCR) Annual Meeting
PR Newswire - Tue Jul 14, 7:30AM CDT
Regen BioPharma Inc (OTCBB: RGBP) (OTC PINK: RGBP) announced today that Dr. Christine Ichim, the Company's Director of Molecular Therapeutics presented preclinical data regarding its DiffronC technology( a constituent of its Differentiation Therapy Platform) at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden on June 24th, 2015.
Regen BioPharma doses mice under its safety and tolerability study of HemaXellerate for aplastic anemia
M2 - Fri Jul 10, 3:36AM CDT
Biotechnology company Regen BioPharma (OTCBB:RGBP) (OTC PINK:RGBP) announced on Thursday the successful dosing of mice lacking an immune system under its safety and tolerability study with its proprietary aplastic anemia cell therapy drug candidate, HemaXellerate.
New Studies & Research Evaluating Stem Cell Therapy Treatments for Bone Marrow Diseases & Conditions Look to Identify Next-Generation Therapies For New Pre-Clinical and Phase I/II Clinical Trials
PR Newswire - Thu Jul 09, 7:30AM CDT
Researchers & Biotech companies are constantly searching for tailor-made treatment plans for bone marrow conditions such as aplastic anemia as part of an emerging precision medicine movement which likely will help doctors optimize treatment for this rare and deadly blood condition. Even with the Biotechnology struggling a bit this week in markets, companies in focus today with news and current developments are Regen BioPharma, Inc. (OTCBB: RGBP), Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), Horizon Pharma plc (NASDAQ: HZNP), AstraZeneca Pharmaceuticals Co. (NYSE: AZN) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
RPTP: 5.99 (+0.10), IRWD: 11.36 (+0.24), AZN: 32.23 (-0.16), HZNP: 19.51 (+1.19), OCLS: 1.22 (+0.03)
Regen BioPharma, Inc. Reports Successful Dosing of HemaXellerate in FDA-Requested GLP Animal Study
PR Newswire - Thu Jul 09, 6:45AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) (OTC: RGBP) reported today the successful dosing of mice lacking an immune system in a safety and tolerability study with HemaXellerate, the Company's proprietary aplastic anemia cell therapy drug candidate. The experiment is being conducted under Good Laboratory Practices (cGLP) by Charles River Laboratories. Charles River Laboratories, established in 1947, is a well respected NYSE-traded contract research organization with 8,500 employees specializing in a variety of pre-clinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries.
Regen BioPharma, Inc. Announces Presentation at the International Society for Stem Cell Research 13th Annual Meeting in Stockholm, Sweden
PR Newswire - Tue Jun 16, 7:30AM CDT
Regen BioPharma Inc (OTCBB: RGBP) (OTC PINK: RGBP) announced today that its abstract was accepted for presentation at the International Society for Stem Cell Research Annual Meeting, June 24-27, in Stockholm, Sweden. Dr. Christine Ichim, the Company's Director of Molecular Therapeutics, will be presenting preclinical data delineating the effects of the Company's gene silencing drugs on stem cells.
Regen BioPharma, Inc. Receives Notice of Allowance for U.S. Patent for Screening of Small Molecules Against Its Nuclear Receptor Target
Marketwired - Fri Jun 12, 9:16AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that it received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application # 13/652,395. This patent, with a priority date of 2008, covers screening mechanisms for identification of small molecules that can modulate the function of a nuclear receptor target that was shown by Dr. Christine Ichim, Regen's Director of Molecular Therapeutics and University of Toronto Hematologist Dr. Richard Wells to be involved in maintenance of the cancer stem cells.
Advanced Immunotherapy Clinical Trials for Cancer Therapies & Breast Cancer Treatments Focus on Developing Innovative Therapeutics & Gene-Silencing Cell Studies
PR Newswire - Wed Jun 10, 7:35AM CDT
Clinical Trials and Innovation Therapies continue to have the potential to drive the pharma and biotech sectors for the final six months of 2015 as forecasts point to the potential for another prosperous year. Cancer new treatments show promise of immuno-oncology therapies as further studies & trials continue to progress. Biotech Companies in focus today are Regen BioPharma, Inc. (OTC: RGBP), Sanofi SA (NYSE: SNY), Vical Incorporated (NASDAQ: VICL), RXi Pharmaceuticals Corporation (NASDAQ: RXII), Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI) & Neuralstem, Inc. (NYSE: CUR)
VICL: 0.43 (unch), RXII: 0.50 (+0.02), RCPI: 0.88 (unch), SNY: 48.75 (+0.03), CUR: 1.33 (+0.03)
Cancer Clinical Trials Expert Dr. Santosh Kesari to Assist Regen BioPharma, Inc. in Addressing FDA Questions Regarding Planned dCellVax Immunotherapy Clinical Trial for Breast Cancer
PR Newswire - Wed Jun 10, 6:55AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) (OTC: RGBP) announced today the initiation of a collaboration with Dr. Santosh Kesari , Professor and Director of Neuro-oncology at University of California San Diego . The goals of the collaboration is to address questions posed by the FDA regarding Regn BioPharma, Inc.'s planned Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer and to modify the existing Investigational New Drug application in order to maximize the probability of clinical trial success . The proposed trial will recruit 10 patients with metastatic breast cancer and will involve 4 monthly injections of the dCellVax gene-silenced dendritic cell therapy. The trial will last one year, with tumor assessment before therapy and at 6 and 12 months.
Regen BioPharma, Inc. Recruits Retinoid Experts Dr. Hinrich Gronemeyer, Dr. William S. Blaner, and Dr. Louise Purton to Serve on Scientific Advisory Board
Marketwired - Thu Jun 04, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the appointment of Dr. Hinrich Gronemeyer, Dr. William S. Blaner, and Dr. Louise Purton to its Scientific Advisory Board. These three experts in the field of retinoid biology have been recruited by Regen BioPharma, Inc. in order to provide the Company with the expertise necessary to accelerate Regen's differentiation therapy small molecule drug discovery platform. This platform aims to design small molecules that can induce differentiation of cancer stem cells by designing ligands to nuclear receptors involved in maintaining stem cell properties of cancer stem cells.
Regen BioPharma Files Patent Application on mRNA Dendritic Cell Cancer Immunotherapeutic
Marketwired - Wed May 27, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the filing of a United States patent application covering mRNA delivered tumor antigens to dendritic cells as a means of inducing tumor immunity. The current work builds upon the Company's Cancer Immunotherapy Platform. This patent application covers intellectual property that provides a means of specifically inducing dendritic cells to internally generate tumor antigens, a process which is believed to be more effective then exogenously administering antigens to dendritic cells. The majority of dendritic cell therapeutics involve "feeding" dendritic cells antigens, this leads to a different type of immune response than if the antigens are generated inside of the dendritic cell.
Regen BioPharma, Inc. Makes Three Presentations at the 13th International Symposium on Myelodysplastic Syndromes Held April 29 to May 2, 2015 in Washington, DC
Marketwired - Tue May 05, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that the Company has made presentations at 13th International Symposium on Myelodysplastic Syndromes held April 29 to May 2, 2015 in Washington, D.C.
